1-[[2-[(2-氯-4-吡啶基)氨基]-4'-(环丙基甲基)[4,5'-联嘧啶]-2'-基]氨基]-2-甲基-2-丙醇 | 1383716-33-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 1-[[2-[(2-氯-4-吡啶基)氨基]-4'-(环丙基甲基)[4,5'-联嘧啶]-2'-基]氨基]-2-甲基-2-丙醇
• 中文别名: VPS34抑制剂(VPS34-IN-1)；1-((2-((2-氯吡啶-4-基)氨基)-4'-(环丙基甲基)-[4,5'-联嘧啶]-2'-基)氨基)-2-甲基丙-2-醇
• 英文名称: 1-((2-((2-chloropyridin-4-yl)amino)-4'-(cyclopropylmethyl)-[4,5'-bipyrimidin]-2'-yl)amino)-2-methylpropan-2-ol
• 英文别名: VPS34-IN1；Vps34-IN-1；1-(2-(2-chloropyridin-4-ylamino)-4'-(cyclopropylmethyl)-4,5'-bipyrimidin-2'-ylamino)-2-methylpropan-2-ol；1-[[5-[2-[(2-chloropyridin-4-yl)amino]pyrimidin-4-yl]-4-(cyclopropylmethyl)pyrimidin-2-yl]amino]-2-methylpropan-2-ol
• CAS: 1383716-33-3
• 化学式: C₂₁H₂₄ClN₇O
• 分子量: 425.921
• InChiKey: AWNXKZVIZARMME-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  30
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  109
• 氢给体数：
  3
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  4-甲基-2-甲硫基嘧啶 在 potassium carbonate 、 间氯过氧苯甲酸 、 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 9.0h， 生成 1-[[2-[(2-氯-4-吡啶基)氨基]-4'-(环丙基甲基)[4,5'-联嘧啶]-2'-基]氨基]-2-甲基-2-丙醇
  参考文献：
  名称：

  [EN] BI-HETEROARYL COMPOUNDS AS VPS34 INHIBITORS
  [FR] COMPOSÉS BI-HÉTÉROARYLES EN TANT QU'INHIBITEURS DE VPS34

  摘要：

  本发明涉及治疗由Vps34高活性特征的疾病或紊乱的新方法，以及作为Vps34抑制剂的化合物；特别是公式I的化合物或其药用盐，以及治疗与Vps34抑制相关的疾病、紊乱或综合症的方法，特别是高增殖性疾病。本发明还包括包括公式I化合物及其药用盐的药物组合物。

  公开号：

  WO2012085815A1

文献信息

• BI-HETEROARYL COMPOUNDS AS VPS34 INHIBITORS
  申请人：Taracido Ivan Cornella

  公开号：US20140155402A1

  公开（公告）日：2014-06-05

  The present invention includes novel methods of treating a disease or disorder characterized by hyperactivity of Vps34, and compound as Vps34 inhibitors; particularly compounds of Formula I: or a pharmaceutically acceptable salt thereof, as well as methods of treating a disease, disorder, or syndrome associated with Vps34 inhibition, particularly hyperproliferative diseases. The present invention also includes pharmaceutical compositions including compounds of formula I and pharmaceutically acceptable salts thereof.

  本发明包括治疗由Vps34高活性所特征的疾病或障碍的新方法，以及作为Vps34抑制剂的化合物；特别是公式I的化合物：或其药学上可接受的盐，以及治疗与Vps34抑制相关的疾病、障碍或综合症的方法，特别是增殖过度性疾病的方法。本发明还包括包括公式I的化合物和其药学上可接受的盐的药物组合物。
• Bi-heteroaryl compounds as Vps34 inhibitors
  申请人：Taracido Ivan Cornella

  公开号：US08685993B2

  公开（公告）日：2014-04-01

  The present invention includes novel methods of treating a disease or disorder characterized by hyperactivity of Vps34, and compound as Vps34 inhibitors; particularly compounds of Formula I or a pharmaceutically acceptable salt thereof, as well as methods of treating a disease, disorder, or syndrome associated with Vps34 inhibition, particularly hyperproliferative diseases. The present invention also includes pharmaceutical compositions including compounds of formula I and pharmaceutically acceptable salts thereof.

  本发明包括治疗由Vps34过度活化引起的疾病或障碍的新方法，以及作为Vps34抑制剂的化合物；特别是公式I的化合物或其药学上可接受的盐，以及治疗与Vps34抑制相关的疾病、障碍或综合征的方法，特别是增殖过度性疾病。本发明还包括包括公式I的化合物及其药学上可接受的盐的制药组合物。
• Optimized Method for Treating and Curing Arthritis, Diabetes, Multiple Sclerosis and Other Autoimmune Disease
  申请人：Postrel Richard

  公开号：US20190070166A1

  公开（公告）日：2019-03-07

  The present invention teaches a method, system and process for curing, treating and diagnosing arthritis, diabetes and other related autoimmune diseases. By intercepting and mitigating the disease process at the point of origination prevents the disease from developing and stops the lineage of cells causing disease symptoms. This fundamental system addresses cellular events where the immune reaction is emerging thereby preventing advance of the cascade that feeds the disease. Modulating activity of the errant protein at this initiating point in the immune response blocks the autoimmune cascade and prevents formation of secondary and tertiary effects that will characterize the disease. As the cascade progresses, the number of participating enzymes and pathways compounds so that each progression step further from the initiation point requires increasingly complex therapies. Thus, by treating the primary cause, secondary and tertiary symptoms do not appear. This avoids the side effects observed in multi-faceted approaches presently used to manage the disease symptoms rather than disease causation.
• US8901147B2
  申请人：——

  公开号：US8901147B2

  公开（公告）日：2014-12-02
• [EN] BIOMARKER<br/>[FR] BIOMARQUEUR
  申请人：SPRINT BIOSCIENCE AB

  公开号：WO2020008046A1

  公开（公告）日：2020-01-09

  An in vitro method of determining the in vivo immunostimulating effect resulting from pharmacological inhibition of Vps34 by a Vps34 inhibitor is disclosed, comprising: in vitro analysing a test sample originating from a source to determine a level of at least one biomarker, wherein the at least one biomarker is selected from the group consisting of CCL2, CCL3, CCL4, CCL5, CXCL9, CXCL10, CXCL11 and IFNγ, and preferably selected from CCL5 and CXCL10, wherein an elevated level of said at least one biomarker in said test sample, relative to a reference level, indicates immunostimulation in said source.